B-cell Acute Lymphoblastic Leukemia Clinical Trials in Philadelphia, Pennsylvania

5 studies are recruiting for b-cell acute lymphoblastic leukemia in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

   Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

   Stage

   Phase 1

   Ages

   0 to 25

   Site

   Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia, Pennsylvania

   Locations

   71 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06395103 on ClinicalTrials.gov

2. A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

   The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will comp…

   Stage

   Phase 3

   Ages

   1 and older

   Site

   Children's Hospital of Philadelphia (Data Collection Only), Philadelphia, Pennsylvania

   Locations

   6 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07223021 on ClinicalTrials.gov

3. Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

   This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even …

   Stage

   Phase 2

   Ages

   7 to 25

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   16 in total

   Run by

   Etan Orgel

   See if you can join NCT05082519 on ClinicalTrials.gov

4. Co-administration of CART22-65s and huCART19 for B-ALL

   This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

   Stage

   Phase 1

   Ages

   Up to 29

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Run by

   Stephan Grupp MD PhD

   See if you can join NCT05674175 on ClinicalTrials.gov

5. Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

   This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the…

   Stage

   Phase 1

   Ages

   15 to 50

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   19 in total

   Run by

   Cellectis S.A.

   See if you can join NCT04150497 on ClinicalTrials.gov